Bispecific antibodies for dual-modality cancer therapy: Killing two signaling cascades with one stone

Current Opinion in Drug Discovery and Development

Volumn 9, Issue 2, 2006, Pages 184-193

  Marvin, Jonathan S ^a   Zhu, Zhenping ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Antibodies; Antibody engineering; Bispecific; Cancer therapy; Dual targeting

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BISPECIFIC ANTIBODY; CETUXIMAB; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DC 101; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMTUZUMAB OZOGAMICIN; GROWTH FACTOR RECEPTOR; IBRITUMOMAB TIUXETAN; IMATINIB; IMC 11F8; IMC A12; IRINOTECAN; METHOTREXATE; MONOCLONAL ANTIBODY; OXALIPLATIN; PERTUZUMAB; PREDNISONE; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ANTIBODY ENGINEERING; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG MANUFACTURE; DRUG POTENTIATION; DRUG RESEARCH; DRUG TARGETING; HUMAN; NONHUMAN; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES; ANTIBODY SPECIFICITY; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 33645054805     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. Govindan SV, Griffiths GL, Hansen HJ, Horak ID, Goldenberg DM: Cancer therapy with radiolabeled and drug/toxin-conjugated antibodies. Technol Cancer Res Treatment (2005) 4(4):375-391.
2. Sharkey RM, Karacay H, Cardillo TM, Chang CH, McBride WJ, Rossi EA, Horak ID, Goldenberg DM: Improving the delivery of radionuclides for Imaging and therapy of cancer using pretargeting methods. Clin Cancer Res (2005) 11(19 Pt 2):7109s-7121s.
3. Longley DB, Harkin DP, Johnston PG: 5-Fluorouracil: Mechanisms of action and clinical strategies. Nat Rev Cancer (2003) 3(5):330-338.
4. No authors listed: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer Evidence in terms of response rate. J Clin Oncol (1992) 10(6):896-903.
5. No authors listed: Meta-analysls of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol (1994) 12(5):960-969.
6. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letoumeau Y, Coudert B, Bertheaut-Cvitkovic F et al: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol (2000) 18(1):136-147.
7. Elias L, Portlock CS, Rosenberg SA: Combination chemotherapy of diffuse histiocytic lymphoma with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP). Cancer (1978) 42(4):1705-1710.
8. Abramson JS, Shipp MA: Advances in the biology and therapy of diffuse large B-cell lymphoma: Moving toward a molecularly targeted approach. Blood (2005) 106(4):1164-1174.
9. Goldenberg DM: Advancing role of radiolabeled antibodies in the therapy of cancer. Cancer Immunol Immunother (2003) 62(5):281-296.
10. Krause DS, Van Etten RA: Tyroslne kinases as targets for cancer therapy. N Engl J Med (2005) 353(2):172-187.
11. Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ, Lemmon MA, Sliwkowski MX, Ward CW, Yokoyama S: An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell (2003) 12(3):541-552.
12. Leahy DJ: Structure and function of the epidermal growth factor (EGF/ErbB) family of receptors. Adv Protein Chem (2004) 68:1-27.
13. Khazaie K, Schirrmacher V, Lichtner RB: EGF receptor in neoplasia and metastasis. Cancer Metastasis Rev (1993) 12(3-4):255-274.
14. Hynes NE, Lane HA: ErbB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer (2005) 5(5):341-354.
15. Moyer JD, Barbacci EG, Iwata KK, Arnold L, Boman B, Cunningham A, DiOrio C, Doty J, Morin MJ, Moyer MP, Neveu M et al: Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res (1997) 57(21):4838-4848.
16. Stamos J, Sliwkowski MX, Eigenbrot C: Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem (2002) 277(48):46265-46272.
17. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med (2005) 353(2)1123-132.
18. Herbst RS, Fukuoka M, Baselga J: Gefitinib - a novel targeted approach to treating cancer. Nat Rev Cancer (2004) 4(12):956-985.
19. Kindler HL, Friberg G, Skoog L, Wade-Oliver K, Vokes EE: Phase I/II trial of gefitinib and oxaliplatin in patients with advanced colorectal cancer. Am J Clin Oncol (2005) 28(4):340-344.
20. Mackenzie MJ, Hirte HW, Glenwood G, Jean M, Goel R, Major PP, Miller VW Jr, Panasci L, Lorimer IA, Batist G, Matthews S et al: A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer. Invest New Drugs (2005) 23(2):165-170.
21. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeler U et al: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1. J Clin Oncol (2004) 22(5):777-784.
22. Herbst RS, Giaccone G, Schiller JM, Natale RB, Miller V, Manegold C, Scagliotti G, Resell R, Oliff I, Reeves JA, Wolf MK et at. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2. J Clin Oncol (2004) 22(5):785-794.
23. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, Lydon NB: Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res (1996) 56(1):100-104.
24. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med (1996) 2(5):561-566.
25. Ren R: Mechanisms of Bcr-Abl in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer (2005) 5(3):172-183.
26. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM: The biology of chronic myeloid leukemia. N Engl J Med (1999) 341(3):164-172.
27. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K et al: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med (2003) 348(11):994-1004.
28. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M et al: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med (2002) 346(9):645-652.
29. Adams GP, Weiner LM: Monoclonal antibody therapy of cancer. Nat Biotechnol (2005) 23(9):1147-1157.
30. Clynes RA, Towers TL, Presta LG, Ravetch JV: Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med (2000) 6(4):443-446.
31. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, U B, Fox JA et al: High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII and FcRn and design of IgG1 variants with improved binding to the FcγR. J Biol Chem (2001) 276(9):6591-6604.
32. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SH, Presta LG: Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcγ RIII and antibody-dependent cellular toxicity. J Biol Chem (2002) 277(30):26733-26740.
33. Kipriyanov SM, Le Gall F: Recent advances in the generation of bispecific antibodies for tumor immunotherapy. Curr Opin Drug Discovery Dev (2004) 7(2):233-242.
34. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med (2004) 361(4):337-345. Provides clinical data on the combination of cetuximab with chemotherapy.
35. Bonner JA, Harari PM, Giralt J, Azarnia N, Cohen RB, Jones C, Sur R, Raben O, Baselga J, Spencer S, Amellal N et al: Cetuximab improves loco-regional control and survival of locoregionally advanced head and neck cancer: Independent review of mature data with a median follow-up of 45 months. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology and Clinical Applications, Philadelphia, PA, USA (2005):B-106. Provides clinical data on the combination of cetuximab with radiotherapy.
36. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 344(11):783-792. Provides clinical data on the combination of trastuzumab with chemotherapy.
37. Thorpe PE: Vascular targeting agents as cancer therapeutics. Clin Cancer Res (2004) 10(2):415-427.
38. Paz K, Zhu Z: Development of angiogenesis inhibitors to vascular endothelial growth factor receptor 2. Current status and future perspective. Front Biosci (2005) 10:1415-1439.
39. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Net Med (2003) 9(6):669-676.
40. Hicklin DJ, Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol (2005) 23(5):1011-1027.
41. Prewett M, Huber J, Li Y, Santiago A, O'Connor W, King K, Overholser J, Hooper A, Pytowski B, Witte L, Bohlen P et al: Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res (1999) 59(20):5209-5218.
42. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E er at PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res (2000) 60(8):2178-2189.
43. Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T et al: AEE788: A dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res (2004) 64(14):4931-4941.
44. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA et al: ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis and tumor growth following oral administration. Cancer Res (2002) 62(16):4645-4655.
45. Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, Smith NR, James NH, Dukes M, Curwen JO, Chester R et al: AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res (2005) 65(10):4389-4400.
46. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (1993) 362(6423):841-844.
47. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res (1997) 57(20):4593-4599.
48. Ferrara N, Hillan KJ, Gerber HP, Novotny W: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov (2004) 3(5):391-400.
49. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E et al: VEGF-trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA (2002) 99(17):11393-11398.
50. Hurwitz H, Fehrenbacher L, Novotny W, Cartwight T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N et al: Bevacizumab plus irinotecan, fluorouracil and leucovorin for metestatic cotorectal cancer. N Engl J Med (2004) 350(23):2335-2342.
51. Madhusudan S, Ganesan TS: Tyrosine kinase inhibitors in cancer therapy. Clin Biochem (2004) 37(7):618-635.
52. Saltz LB, Lenz H, Hochster H, Wadler S, Hoff P, Kemeny N, Hollywood E, Gonen M, Wetherbee S, Chen H: Randomized phase II trial of cetuximab/ bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. American Society of Clinical Oncology Annual Meeting, Orlando, FL, USA (2005):Abs 3508. Provides clinical data on the combination of cetuximab with bevacizumab.
53. Jung YD, Mansfield PF, Akagi M, Takeda A, Liu W, Bucana CD, Hicklin DJ, Ellis LM: Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur J Cancer (2002) 38(8):1133-1140.
54. Shaheen RM, Ahmad SA, Liu W, Reinmuth N, Jung YD, Tseng WW, Drazan KE, Bucana CD, Hicklin DJ, Ellis LM: Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br J Cancer (2001 85(4):584-589.
55. Lamszus K, Brockmann MA, Eckerich C, Bohlen P, May C, Mangold U, Filibrandt R, Westphal M: Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor and vascular endothelial-cadherin. Clin Cancer Res (2005) 11(13):4934-4940.
56. Penar PL, Khoshyomn S, Bhushan A, Tritton TR: Inhibition of epidermal growth factor receptor-associated tyrosine kinase blocks glioblastoma invasion of the brain. Neurosurgery (1997) 40(1):141-151.
57. Kunkel P, Ulbricht U, Bohlen P, Brockmann MA, Fillbrandt R, Stavrou D Westphal M, Lamszus K: Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res (2001) 61(18):6624-6628.
58. Chakravarti A, Loeffler JS, Dyson NJ: Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling Cancer Res (2002) 62(1):200-207.
59. Krane JF, Murphy DP, Carter DM, Krueger JG: Synergistic effects of epidermal growth factor (EGF) and insulin-like growth factor lisomatomedin C (IGF-I) on keratinocyte proliferation may be mediated by IGF-I transmodulation of the EGF receptor. J Invest Dermatol (1991) 96(4):419-424.
60. Kobari M, Kullenberg B, Bjorkman A, Matsuno S, Ihse I, Axelson J: The inhibitory effect of an EGF receptor-specific tyrosine kinase inhibitor on pancreatic cancer cell lines was more potent than inhibitory antibodies against the receptors for EGF and IGF I. Int J Pancreatol (1998) 24(2):85-95.
61. Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS, Bassi R, Abdullah R, Hooper AT, Koo H, Jimenez X et al: A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res (2003) 63(24):8912-8921.
62. Lu D, Zhang H, Koo H, Tonra J, Balderes P, Prewett M, Corcoran E, Mangalampalli V, Bassi R, Anselma D, Patel D et al: A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem (2005) 280(20):19665-19672. Describes the construction of an IgG-like BsAb targeting two growth factor signaling pathways.
63. Ye D, Mendelsohn J, Fan Z: Augmentation of a humanized anti-HER2 mAb 406 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Oncogene (1999) 18(3):731-738.
64. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW Jr, Leahy DJ: Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature (2003) 421(6924):756-760.
65. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J: Trastuzumab (herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells. Cancer Res (2001) 61(12):4744-4749.
66. Fendly BM, Winget M, Hudziak RM, Lipari MT, Napier MA, Ullrich A: Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product Cancer Res (1990) 50(5):1550-1558.
67. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX: Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell (2004) 5(4):317-328.
68. Agus OB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K, Scher HI et al: Targeting ligand-activated ErB2 signaling inhibits breast and prostate tumor growth. Cancer Cell (2002) 2(2):127-137.
69. Nahta R, Hung MC, Esteva FJ: The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res (2004) 64(7):2343-2346.
70. Barr IG, MacDonald HR, Buchegger F, von Fliedner V: Lysis of tumor cells by the retargeting of murine cytolytic T lymphocytes with bispecific antibodies. Int J Cancer (1987) 40(3):423-429.
71. Kontermann RE: Recombinant bispecific antibodies for cancer therapy. Acta Pharmacol Sin (2005) 26(1):1-9. Provides a good review of BsAb fragments.
72. Graff CP, Wittrup KD: Theoretical analysis of antibody targeting of tumor spheroids: Importance of dosage for penetration and affinity for retention. Cancer Res (2003) 63(6):1288-1296.
73. Chang CH, Sharkey RM, Rossi EA, Karacay H, McBride W, Hansen HJ, Chatal JF, Barbet J, Goldenberg DM: Molecular advances in pretargeting radioimunotherapy with bispecific antibodies. Mol Cancer Ther (2002) 1(7):553-563.
74. Ford CH, Osborne PA, Rego BG, Mathew A: Bispecific antibody targeting of doxorubicin to carcinoembryonic antigen-expressing colon cancer cell lines in vitro and in vivo. Int J Cancer (2001) 92(6):851-855.
75. Marvin JS, Zhu Z: Recombinant approaches to IgG-like bispecific antibodies. Acta Pharmacol Sin (2005) 26(6):649-658. Provides a review of the different formats for constructing IgG-like BsAb.
76. Lu D, Zhang H, Ludwig D, Persaud A, Jimenez X, Burtrum D, Balderes P, Liu M, Bohlen P, Witte L, Zhu Z: Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody. J Biol Chem (2004) 279(4):2856-2865. Describes the construction of an IgG-like BsAb targeting two growth factor signaling pathways.
77. Zhu Z, Presta LG, Zapata G, Carter P: Remodeling domain interfaces to enhance heterodimer formation. Protein Sci (1997) 6(4):781-788.
78. Jung SH, Pastan I, Lee B: Design of interchain disulfide bonds in the framework region of the Fv fragment of the monoclonal antibody B3. Proteins (1994) 19(1):35-47.
79. FitzGerald K, Holliger P, Winter G: Improved tumour targeting by dlsulphlde stabilized diabodies expressed in Pichia pastoris. Protein Eng (1997) 10(10):1221-1225.
80. Worn A, Pluckthun A: Stability engineering of antibody single-chain Fv fragments. J Mol Biol (2001) 305(5):989-1010.
81. Lu D, Jimenez X, Zhang H, Wu Y, Bohlen P, Witte L, Zhu Z: Complete Inhibition of vascular endothelial growth factor (VEGF) activities wtth a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor. Cancer Res (2001) 61(19):7002-7008.
82. Jimenez X, Lu D, Brennan L, Persaud K, Liu M, Miao H, Witte L, Zhu Z: A recombinant, fully human, bispecific antibody neutralizes the biological activities mediated by both vascular endothelial growth factor receptors 2 and 3. Mol Cancer Ther (2005) 4(3):427-434.
83. Milstein C, Cuello AC: Hybrid hybridomas and their use in immunohistochemistry. Nature (1983) 306(5934):537-540.
84. Holliger P, Hudson PJ: Engineered antibody fragments and the rise of single domains. Nat Biotechnol (2005) 23(9):1126-1136.
85. Lu D, Kotanides H, Jimenez X, Zhou Q, Persaud K, Bohlen P, Witte L, Zhu Z: Acquired antagonistic activity of a bispecific diabody directed against two different epitopes on vascular endothelial growth factor receptor 2. J Immunol Methods (1999) 230(1-2):159-171.
86. Jendreyko N, Popkov M, Beerli RR, Chung J, McGavern DB, Rader C, Barbas CF: Intradiabodies, bispecific, tetravalent antibodies for the simultaneous functional knockout of two cell surface receptors. J Biol Chem (2003) 278(48):47812-47819. Describes the construction of an IgG-like bispecific intrabody targeting two angiogenesis receptors.
87. Jendreyko N, Popkov M, Rader C, Barbas CF 3rd: Phenotypic knockout of VEGF-R2 and Tle-2 with an intradiabody reduces tumor growth and angiogenesis in vivo. Proc Natl Acad Sci USA (2005) 102(23):8293-8298. Describes the construction and in vivo activity of an IgG-like bispecific intrabody targeting two angiogenesis receptors.
88. Heng BC, Cao T: Making cell-permeable recombinant telomerase (trans-telomerase) through fusion of Its catalytic subunit (hTERT) with protein transduction domains (PTD): A possible strategy to overcome replicative senescence during ex vivo culture of primary explanted cells. Med Hypotheses (2005) 65(1):199-200.
89. Cao T, Heng BC: Intracellular antibodies (intrabodies) versus RNA interference for therapeutic applications. Ann Clin Lab Sci (2005) 35(3):227-229.
90. Volk WA, Bizzini B, Snyder RM, Bernhard E, Wagner RR: Neutralization of tetanus toxin by distinct monoclonal antibodies binding to multiple epitopes on the toxin molecule. Infect Immun (1984) 45(3):604-609.
91. Nowakowski A, Wang C, Powers DB, Amersdorfer P, Smith TJ, Montgomery VA, Sheridan R, Blake R, Smith LA, Marks JD: Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci USA (2002) 99(17):11346-11350.
92. Haurum J, Bregenholt S: Recombinant polyclonal antibodies: Therapeutic antibody technologies come full circle. IDrugs (2005) 8(5):404-409.
93. Sharon J, Liebman MA, Williams BR: Recombinant polyclonal antibodies for cancer therapy. J Cell Biochem (2005) 96(2):305-313.
94. Williams BR, Sharon J: Polyclonal anti-colorectal cancer Fab phage display library selected in one round using density gradient centrifugation to separate antigen-bound and free phage. Immunol Lett (2002) 81(2):141-148.
95. Williams BR, Sompuram SR, Sharon J: Generation of anti-colorectal cancer Fab phage display libraries with a high percentage of diverse antigen-reactive clones. Comb Chem High Throughput Screen (2002) 6(6):489-499.
96. Liebman MA, Williams BR, Daley KM, Sharon J: Generation and preliminary characterization of an antibody library with preferential reactivity to human colorectal cancer cells as compared to normal human blood cells. Immunol Lett (2004) 91(2-3):179-188. Reference to patent literature
97. XENCOR INC (Lazar GA, Chirino AJ, Dang W, Desjarlais JR, Doberstein SK, Hayes RJ, Karki SB, Vafa O): Optimized Fc variants and methods for their generation. US-20050054832 (2005).